Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KP-470
- Development stage
- Preclinical
- Lead developer
- Kaken Pharmaceutical
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
KP-470 is a small molecule, investigational topical drug developed by Kaken Pharmaceutical for the treatment of psoriasis. Its mechanism of action is currently classified as undefined, distinguishing it from other antipsoriatic and antirheumatic agents. The compound is a new molecular entity, and as of the latest updates, has only reached preclinical development, with research primarily focused in Japan. Licensing arrangements with other companies outside Japan have lapsed, and there are no publicly available clinical trial results or detailed target data.
- Other names
- KP 470KP470KP-470
Beyond the preview
Go deeper on KP-470.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KP-470.